论文部分内容阅读
目的对乙肝相关性原发性肝癌预后因素进行分析,并探究其抗病毒治疗的价值。方法选取2013年2月-2016年2月医院感染科收治的乙肝相关性原发性肝癌患者80例,患者均接受抗病毒治疗,对其治疗结局及预后指标进行观察分析。结果对乙肝相关性原发性肝癌患者经抗病毒治疗后的预后相关预测因素进行单因素分析,发现HCC分级(3级)、肿瘤数目(多处)、HBe阳性抗原(有)、糖尿病(有)是影响其预后的相关因素。进行多因素分析,发现HBe阳性抗原(有)是影响其预后的相关因素。结论 HBe阳性抗原可能是影响乙肝相关性原发性肝癌预后的主要因素,加强患者的抗病毒治疗,可促进其预后的改善。
Objective To analyze the prognostic factors of hepatitis B-related primary hepatocellular carcinoma (HCC) and to explore the value of antiviral therapy. Methods From February 2013 to February 2016, 80 patients with hepatitis B-related primary hepatocellular carcinoma (HCC) admitted to the hospital infection department were enrolled in this study. All patients were treated with antiviral therapy, and their therapeutic outcomes and prognostic indicators were observed and analyzed. Results Univariate analysis showed that the prognosis-related predictors of HBV-related primary hepatocellular carcinoma after antiviral therapy were univariate analysis and found that the number of HCC grading (grade 3), the number of tumors (multiple sites), HBe-positive antigen ) Is related to the prognosis of the factors. Multivariate analysis showed that HBe-positive antigen (a) was the related factor that affected its prognosis. Conclusion HBe-positive antigen may be the main factor influencing the prognosis of hepatitis B-related primary hepatocellular carcinoma. Strengthening antiviral therapy can promote its prognosis.